[REVISION HISTORY]
US expands statin and hypertension eligibility
2 recorded revisions of this situation.
What changed
2026-08-05 03:26 UTC → 2026-08-15 21:21 UTC ·
added
removed
US expands statin and hypertension eligibility under new guidelines
In late July 2026 2026, the American College of Cardiology and the American Heart Association issued primary‑prevention primary-prevention updates that lowered risk thresholds for dyslipidemia and hypertension. The dyslipidemia guidance introduced the PREVENT risk calculator and added roughly 21.5 million adults aged 30‑79 30-79 to statin eligibility, while shifting emphasis toward lifelong prevention. Analysis of National Health and Nutrition Examination Survey data indicates that approximately 87.5 million U.S. adults—about 56.6% of the population in that age range—are now eligible. This includes a significant expansion for younger individuals, with the minimum prescribing age lowered from 40 to 30. The hypertension update applied the same PREVENT model to expand blood‑pressure blood-pressure drug coverage to about 22‑23 22-23 million adults. However, data shows a significant treatment gap, with approximately 43% of those newly eligible—roughly 9.7 million people—not receiving any treatment. Researchers estimate that addressing this gap could prevent up to 200,000 premature deaths over the next decade. A follow‑up follow-up report on 3 August 2026 clarified that the cholesterol guideline now lowers the minimum prescribing age from 40 to 30, bringing total statin‑eligible expansion means over 93% of adults to an estimated 87.5 million. aged 70-79 and 85% of those aged 60-69 now qualify. The expansion is driven by internal‑medicine internal-medicine researcher Timothy Anderson and endorsed by the American Heart Association and related societies. The report also cited a Association. A JAMA analysis showing cited in these reports noted that elevated LDL‑C LDL-C caused 3.6 million deaths in 2023, underscoring the global health impact of the U.S. policy shift. 2023. Regarding affordability, Medicare typically covers common generic statins, such as atorvastatin, rosuvastatin, and simvastatin, through Medicare Advantage or Part D plans, though brand-name versions may require prior authorization.
Versions
- 2026-08-15 21:21 UTC US expands statin and hypertension eligibility
- 2026-08-05 03:26 UTC US expands statin eligibility under new guidelines
- 2026-07-29 21:19 UTC US cardiovascular guideline expansion
Select a version to see what changed compared to the one before it.